Learn About Our Services
HEMLIBRA Access Solutions is your resource for access and
reimbursement support after HEMLIBRA is prescribed.
Coverage
Help understanding benefits and coverage, such as benefits investigations and prior authorization resources
Product Distribution
A list of authorized distributors, specialty pharmacies as well as information on our Spoilage Replacement Program. All treatment center pharmacies are in-network
Online Patient Enrollment
Submit HEMLIBRA Access Solutions forms and check the status of your service requests online using My Patient Solutions
Our Commitment to Patients
Over the past 20+ years,
Genentech has helped over
2 million
patients access the Genentech medicines they need.
In 2018, we helped more than
270,000
patients access the Genentech medicines they need.
Communication assistance services
HEMLIBRA Access Solutions employs a multilingual call center
staff and offers teletypewriter (TTY) services for callers.
Important Safety Information & Indication
Indication
HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A with or without factor VIII inhibitors.
Important Safety Information
Boxed WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM
Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.
Warnings and Precautions
- Laboratory coagulation test interference: HEMLIBRA interferes with activated clotting time (ACT); activated partial thromboplastin time (aPTT); and coagulation laboratory tests based on aPTT, including one-stage, aPTT-based single-factor assays; aPTT-based Activated Protein C Resistance (APC-R); and Bethesda assays (clotting-based) for factor VIII (FVIII) inhibitor titers. Intrinsic pathway clotting-based laboratory tests should not be used
Most Common Adverse Reactions
The most common adverse reactions (incidence ≥10%) are injection site reactions, headache, and arthralgia.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see the HEMLIBRA full Prescribing Information for additional Important Safety Information, including Boxed WARNING.